Merck & Co., Inc. (MRK) Revenue by Segment
Merck & Co., Inc. revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Merck & Co., Inc.'s largest business segment was Pharmaceutical, with $14.76 billion or 89% of revenue, up 5.1% from a year earlier. Next: Animal Health (11%).
By product or service, Keytruda brought in 48%, Gardasil/Gardasil 9 brought in 7% and Livestock brought in 6% of revenue in Q2 fiscal 2026.
By region, United States brought in 56%, EMEA brought in 24% and Latin America brought in 5% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was Animal Health (+7.8%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Merck & Co., Inc.
Revenue breakdown
Fiscal quarters, from company filings
Merck & Co., Inc. revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Pharmaceutical | $14.8B | $14.3B | $15.6B | $14.1B | 89% |
| Animal Health | $1.8B | $1.8B | $1.6B | $1.6B | 11% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Merck & Co., Inc. revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Keytruda | $7.9B | $7.9B | $8.1B | $8.0B | 48% |
| Gardasil/Gardasil 9 | $1.2B | $1.1B | $1.7B | $1.1B | 7% |
| Livestock | $1.0B | $1.1B | $1.0B | $961.0M | 6% |
| Companion Animal | $734.0M | $727.0M | $592.0M | $685.0M | 4% |
| Other Pharmaceutical | $643.0M | $775.0M | $953.0M | $703.0M | 4% |
| ProQuad MMR II Varivax | $592.0M | $538.0M | $684.0M | $609.0M | 4% |
| Winrevair | $588.0M | $525.0M | $360.0M | $336.0M | 4% |
| Bridion | $497.0M | $472.0M | $439.0M | $461.0M | 3% |
| Keytruda Qlex | $463.0M | $128.0M | – | – | 3% |
| Alliance revenue - Lynparza | $365.0M | $341.0M | $379.0M | $370.0M | 2% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Merck & Co., Inc. revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $9.4B | $9.2B | $10.0B | $8.8B | 56% |
| EMEA | $3.9B | $3.9B | $3.7B | $3.7B | 24% |
| Latin America | $875.0M | $874.0M | $905.0M | $859.0M | 5% |
| Asia Pacific | $820.0M | $738.0M | $764.0M | $785.0M | 5% |
| Other Countries | $640.0M | $679.0M | $798.0M | $595.0M | 4% |
| Japan | $577.0M | $555.0M | $712.0M | $626.0M | 3% |
| China | $408.0M | $390.0M | $405.0M | $446.0M | 2% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Merck & Co., Inc.'s business segments?
Pharmaceutical and Animal Health (as reported for Q2 fiscal 2026).
Which business segment makes the most money for Merck & Co., Inc.?
Pharmaceutical: $14.76 billion, or 89% of revenue, in Q2 fiscal 2026.
What are Merck & Co., Inc.'s main products and services?
By revenue in Q2 fiscal 2026: Keytruda (48%), Gardasil/Gardasil 9 (7%), Livestock (6%) and Companion Animal (4%).
Where does Merck & Co., Inc. make its money?
By region in Q2 fiscal 2026: United States (56%), EMEA (24%), Latin America (5%) and Asia Pacific (5%).
